ArticleCureus2025
Impact of an Asymmetric Cellulose Triacetate (ATA) Membrane on Interleukin-6 Clearance and Pressure Stability During Continuous Hemofiltration in an Ex Vivo Sepsis Model.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAsymmetric cellulose triacetate (ATA) membranes have been developed to improve filtration performance and biocompatibility in blood purification therapy. However, their efficacy in cytokine removal and their long-term durability have not been comprehensively evaluated.
methodsAn ex vivo sepsis model was established by incubating human whole blood samples with lipopolysaccharide for 12 hours. Two hemofilter types, ATA and conventional cellulose triacetate (CTA), were compared using a continuous hemofiltration circuit. Interleukin (IL)-6 levels and albumin clearance were measured over 24 hours. The intracircuit pressure was monitored to evaluate the membrane durability.
resultsThe ATA membrane achieved significantly higher IL-6 clearance (mean 20.7 (IQR, 17.5-24.5) mL/minute) than the CTA membrane (mean 12.6 (IQR, 10.2-14.9) mL/minute; p = 0.0125). The ATA membrane also demonstrated greater albumin clearance than the CTA membrane (mean 0.74 (IQR, 0.42-0.92) mL/minute vs. mean 0.09 (IQR, 0.07-0.10) mL/minute; p = 0.0039). The ATA membrane demonstrated more stable transmembrane pressure profiles than CTA membranes across the 24-hour observation period.
conclusionATA membranes exhibit enhanced cytokine removal capacity and favorable pressure stability compared with conventional CTA membranes. These findings suggest the potential clinical utility of ATA membranes in conditions requiring efficient mediator clearance, although albumin loss should be carefully considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.